Related MeSH Hierarchy (7)
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Urogenital Neoplasms » Genital Neoplasms, Female » Uterine Neoplasms » Uterine Cervical Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Uterine Diseases » Uterine Cervical Diseases » Uterine Cervical Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Uterine Diseases » Uterine Neoplasms » Uterine Cervical Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Neoplasms » Genital Neoplasms, Female » Uterine Neoplasms » Uterine Cervical Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Uterine Diseases » Uterine Cervical Diseases » Uterine Cervical Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Uterine Diseases » Uterine Neoplasms » Uterine Cervical Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Genital Neoplasms, Female » Uterine Neoplasms » Uterine Cervical Neoplasms
Description
Tumors or cancer of the UTERINE CERVIX. MeSH
Hierarchy View
Approved Indicated Drugs (3)
Phase 3 Indicated Drugs (67)
Phase 2 Indicated Drugs (184)
11-valent recombinant human papilloma virus vaccine
acetylsalicylic acid (aspirin)
attenuated live listeria encoding hpv 16 e7 vaccine
autologous hematopoietic stem cells
F 18-fluoroazomycin arabinoside (faza)
human papillomavirus 16 e7 peptide
liposomal hpv-16 e6/e7 multipeptide vaccine pds0101
recombinant adenoviral human p53 gene
recombinant human adenovirus type 5
Phase 1 Indicated Drugs (98)
124i-iodo-azomycin galacto-pyranoside
allogeneic natural killer cells
Other Experimental Indicated Drugs (25)
Organization Involved with Phase 4 Indications (30)
All India Institute of Medical Sciences
Cancer Prevention and Research Institute, Italy
Centers for Disease Control and Prevention (CDC)
Chinese Academy of Medical Sciences
Gujarat Cancer & Research Institute
International Agency for Research on Cancer
International Union Against Cancer, Switzerland
Organization Involved with Phase 3 Indications (134)
Agogo Presbyterian Hospital, Ghana
Air Force Military Medical University, China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Boryung Pharmaceutical Company
Brockhoff Foundation Australia
Delaware County Memorial Hospital
Department of Radiation Oncology
Eastern Cooperative Oncology Group
El Kendi Pharmaceuticals Manufacturing Company
European Network for Gynaecological Oncological Trial Groups
European Organisation for Research and Treatment of Cancer
Government Royapettah Hospital
Health and Family Planning Commission of Jiangsu Province, China
Hospital Alessandro Manzoni Lecco
Huazhong University of Science and Technology
Inner Mongolia Medical University
Institut de Cancérologie de Lorraine
Institut fuer Frauengesundheit
International Atomic Energy Agency
International Center for Diarrheal Disease Research
Jiangsu Cancer Institute & Hospital
Jilin Provincial Tumor Hospital
National Research Council of Thailand
National University of Singapore
NHMRC CCRE in Childhood and Adolescent Immunisation
Radiation Therapy Oncology Group
Organization Involved with Phase 2 Indications (197)
Academic Medical Organization of Southwestern Ontario
Asian Gynecologic Oncology Group
Biotech Pharmaceutical Co., Ltd.
Cancer Biotherapy Research Group
Cancer Institute Hospital, Japan
Case Western Reserve University
Central and Eastern European Oncology Group
Chao Family Comprehensive Cancer Center
Chinese Anti-Cancer Association
Chittaranjan National Cancer Institute
Grupo Español de Investigación en Cáncer de Ovario
Grupo Oncologico Cooperativo del Sur
GSO Global Clinical Research BV
Guangzhou Gloria Biosciences Co., Ltd.
Herbert Irving Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
Holy Name Medical Center, Teaneck, NJ
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
Innovent Biologics (Suzhou) Co. Ltd.
Instituto de Medicina Integral Professor Fernando Figueira
Instituto Nacional de Cardiologia Ignacio Chavez
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
James Graham Brown Cancer Center
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Katholieke Universiteit Leuven
Moorgreen Hospital, Southampton
Multicenter Italian Trials in Ovarian Cancer
National Cancer Institute, France
National Cheng Kung University
National Comprehensive Cancer Network
National Institutes of Health (NIH)
Nordic Society for Gynaecologic Oncology
North Eastern Germany Society of Gynaecologic Oncology
PGOG (Polish Gynaecologic Oncology Group)
Royal Marsden Hospital NHS Trust
Shenzhen Geno-Immune Medical Institute
Shenzhen Hank Bioengineering Institute
State University of New York, Buffalo
Taichung Veterans General Hospital
Taiwanese Gynecologic Oncology Group
Uniformed Services University of the Health Sciences
Universidad Autonoma de Barcelona
Universidad Nacional de Colombia
Universita' Cattolica del Sacro Cuore
University of Alabama, Birmingham
University of California, Irvine
University of California, San Francisco
University of Campania Luigi Vanvitelli
University of Medicine and Dentistry of New Jersey
University of Southern California
Virginia Commonwealth University
Washington University in St. Louis
Women's Cancer Center - Los Gatos
Organization Involved with Phase 1 Indications (39)
Cancer and Leukemia Group B (CALGB)
City of Hope National Medical Center
Instituto Nacional de Enfermadades Neoplasticas (INEN)
National Institute for Health Research, United Kingdom
Ontario Institute for Cancer Research
Organization Involved with Other Experimental Indications (15)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.